GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

Trial Details

NCT ID
NCT07297667
Phase
PHASE1
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Fludarabine
  • Cyclophosphamide
  • GCAR1
Locations (sample)
  • Calgary, Alberta, Canada|51.05011,-114.08529
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Archival tumour specimen must be positive for GPNMB with high expression by immunohistochemistry (central laboratory testing).
  • Histologically and/or cytologically confirmed diagnosis of one of the following tumours that is advanced/ metastatic/ recurrent or unresectable, fo…
  • alveolar soft part sarcoma
  • renal cell carcinoma (excluding clear cell)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →